Who we are

Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients and is building a fully integrated, next-generation CAR T company

About us

Abstracts and Publications

See all
Nature Medicine
July 06 2023

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Molecular Therapy
March 21 2023

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

December 12 2022

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)

Information for patients

Clinical trials are required to gain regulatory approval for new medicines to advance patient care.

Learn more about our CAR T cell therapy clinical trials

Life at Autolus

Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus.

Careers at Autolus


Autolus is building a fully-integrated, next generation CAR T company. It is committed to the development and commercialization of obe-cel in r/r Adult ALL and is progressing opportunities for obe-cel in additional indications alongside its preclinical and clinical pipeline for hematological malignancies and solid tumors.

View investor information